179 related articles for article (PubMed ID: 1394037)
1. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.
Pazdur R; Ajani JJ; Abbruzzese JL; Belt RJ; Dakhil SR; Dubovsky D; Graham S; Pilat S; Winn R; Levin B
Cancer; 1992 Oct; 70(8):2073-6. PubMed ID: 1394037
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma.
Pazdur R; Ajani JA; Winn R; Bearden J; Belt RJ; Pilat S; Hallinan R; Levin B
Cancer; 1992 Feb; 69(4):878-82. PubMed ID: 1735078
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
Pazdur R; Ajani JA; Patt YZ; Gomez J; Bready B; Levin B
Cancer; 1993 Feb; 71(4):1214-8. PubMed ID: 8435795
[TBL] [Abstract][Full Text] [Related]
4. 5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules.
John WJ; Neefe JR; Macdonald JS; Cantrell J; Smith M
Cancer; 1993 Dec; 72(11):3191-5. PubMed ID: 8242541
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Hudes GR; Lipsitz S; Grem J; Morrisey M; Weiner L; Kugler JW; Benson A
Cancer; 1999 Jan; 85(2):290-4. PubMed ID: 10023694
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.
Bernhard H; Jäger-Arand E; Bernhard G; Heike M; Klein O; Riemann JF; Meyer zum Büschenfelde KH; Dippold W; Knuth A
Br J Cancer; 1995 Jan; 71(1):102-5. PubMed ID: 7819023
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
9. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Wadler S; Damle S; Haynes H; Kaleya R; Schechner R; Berkenblit R; Ladner RD; Murgo A
J Clin Oncol; 1999 Jun; 17(6):1771-8. PubMed ID: 10561214
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
Wadler S; Goldman M; Lyver A; Wiernik PH
Cancer Res; 1990 Apr; 50(7):2056-9. PubMed ID: 2317795
[TBL] [Abstract][Full Text] [Related]
11. Combination fluorouracil, folinic acid, and interferon alfa-2a: an active regimen in advanced pancreatic carcinoma.
Knuth A; Bernhard H; Klein O; Meyer zum Büschenfelde KH
Semin Oncol; 1992 Apr; 19(2 Suppl 3):211-4. PubMed ID: 1557650
[TBL] [Abstract][Full Text] [Related]
12. Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.
Schmoll HJ; Köhne-Wömpner CH; Hiddemann W; Knipp H; Wilke H; Bodenstein H; Schöffski P; Bokemeyer C; Lohrmann HP; Preiss J
Semin Oncol; 1992 Apr; 19(2 Suppl 3):191-6. PubMed ID: 1557646
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma.
Kim J; Zhi J; Satoh H; Koss-Twardy SG; Passe SM; Patel IH; Pazdur R
Anticancer Drugs; 1998 Sep; 9(8):689-96. PubMed ID: 9823427
[TBL] [Abstract][Full Text] [Related]
14. Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan-Kettering experience.
Kemeny N; Younes A
Semin Oncol; 1992 Apr; 19(2 Suppl 3):171-5. PubMed ID: 1557642
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.
Sparano JA; Lipsitz S; Wadler S; Hansen R; Bushunow PW; Kirkwood J; Flynn PJ; Dutcher JP; Benson AB
Am J Clin Oncol; 1996 Dec; 19(6):546-51. PubMed ID: 8931668
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II study of 5-fluorouracil, recombinant interferon alpha2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus.
Damle S; Beitler JJ; Haynes H; Camacho M; Wolf E; Wadler S
Am J Clin Oncol; 1999 Aug; 22(4):391-5. PubMed ID: 10440197
[TBL] [Abstract][Full Text] [Related]
17. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours.
Hughes MJ; Kerr DJ; Cassidy J; Soukop M; McGregor K; Blackburn N; Yosef H; Kaye SB
Ann Oncol; 1996 Feb; 7(2):208-10. PubMed ID: 8777180
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
